-
Product Insights
Delayed Graft Function (DGF) - Drugs In Development, 2024
Empower your strategies with our Delayed Graft Function (DGF) – Drugs In Development, 2024 report and make more profitable business decisions. Delayed graft function (DGF) is an indication of acute kidney injury (AKI) occurring after a kidney transplant, with attributes unique to the transplant process. AKI is defined as an increase in serum creatinine within 48 hours of an inciting event. In the case of a transplant, the timing is less straightforward. The diagnosis of DGF is complicated by a variety...
-
Product Insights
Corneal Graft Rejection - Drugs In Development, 2024
Empower your strategies with our Corneal Graft Rejection – Drugs In Development, 2024 report and make more profitable business decisions. Corneal graft rejection comprises a sequence of complex immune responses that involves the recognition of the foreign histocompatibility antigens of the corneal graft by the host's immune system, leading to the initiation of the immune response cascade. An efferent immune response is mounted by the host immune system against these foreign antigens culminating in rejection and graft decompensation in irreversible cases...
-
Product Insights
Immunoglobulin G4-Related Disease (IgG4-RD) - Drugs In Development, 2024
Empower your strategies with our Immunoglobulin G4-Related Disease (IgG4-RD) – Drugs In Development, 2024 report and make more profitable business decisions. Immunoglobulin-G4 related disease is an immune-mediated condition that can affect multiple organ systems. It is a fibro-inflammatory condition with tumefactive lesions of unknown etiology and characteristic histopathological features. This is also known as IgG4-related systemic disease, hyper-IgG4 disease, IgG4-related autoimmune disease, IgG4-associated disease, IgG4-related sclerosing disease, and IgG4-syndrome. The Immunoglobulin G4-Related Disease (IgG4-RD) drugs in development market research report provide...
-
Product Insights
Juvenile Rheumatoid Arthritis - Drugs In Development, 2024
Empower your strategies with our Juvenile Rheumatoid Arthritis – Drugs In Development, 2024 report and make more profitable business decisions. Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in kids and teens. It typically causes joint pain and inflammation in the hands, knees, ankles, elbows and/or wrists. But, it may affect other body parts too . JIA used to be called juvenile rheumatoid arthritis (JRA), but the name changed because it is not a kid version of the...
-
Product Insights
Pancreatic Islet Transplant Rejection - Drugs In Development, 2024
Empower your strategies with our Pancreatic Islet Transplant Rejection – Drugs In Development, 2024 report and make more profitable business decisions. Pancreatic Islet Transplant Rejection is a process in which a transplant recipient's immune system attacks the transplanted Pancreatic Islets. Various mechanisms involving chronic inflammation, humoral, and cellular immune reactions play essential roles in the immunopathogenesis of rejections The Pancreatic Islet Transplant Rejection drugs in development market research report provide comprehensive information on the therapeutics under development for Pancreatic Islet Transplant...
-
Product Insights
Subacute Cutaneous Lupus Erythematosus (SCLE) - Drugs In Development, 2024
Empower your strategies with our Subacute Cutaneous Lupus Erythematosus (SCLE) – Drugs In Development, 2024 report and make more profitable business decisions. Subacute cutaneous lupus (SCLE) is an autoimmune disorder, that occurs when the immune system attacks itself. This is a subtype of CLE presenting as symmetric, non-scarring photosensitive erythematous rash usually over syn-exposed areas like face, neck, arms, upper back, and shoulders that causes skin rashes or lesions (sores). The Subacute Cutaneous Lupus Erythematosus (SCLE) drugs in development market research...
-
Thematic Analysis
Cell and Gene Therapies in Rheumatology - Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in Rheumatology Market Report Overview The market size for cell and gene therapies (CGT) in rheumatic diseases by molecule type is estimated to be $24 million in 2024. Cell therapies will continue to dominate the CGT market in rheumatic diseases. This growth is attributed to the high number of cell therapy assets in the pipeline and increasing interest in rheumatic diseases due to the increasing prevalence and high unmet need, especially as the aging population increases....
-
Thematic Analysis
Digital Marketing Trends in Rheumatoid Arthritis
Digital Marketing Trends in Rheumatoid Arthritis Report Overview AbbVie’s Rinvoq.com achieved the highest total traffic across Rheumatoid Arthritis (RA) patient sites in the US, from February 2023 to January 2024. This was followed by AbbVie’s Humira.com. Overall, the highest proportion of traffic to top branded patient RA websites originated from direct sources, followed by organic. Buy the Full Report to get More Insights into the Digital Marketing Trends in Rheumatoid Arthritis Download a Free Report Sample The ‘Digital Marketing Trends...
-
Thematic Analysis
Digital Marketing Trends in Psoriasis
Digital Marketing Trends in Psoriasis Report Overview AbbVie’s Skyrizi.com accounted for the highest traffic across branded psoriasis (PsO) patient sites in the US, with around three million visitors from January 2023 to December 2023. This was followed by Amgen’s Otezla.com (1.7 million visits). Overall, the highest proportion of traffic to top branded patient PsO websites originated from organic sources, followed by direct searches. Buy the Full Report to get More Insights into the Digital Marketing Trends in Psoriasis Download a...
-
Sector Analysis
Rheumatoid Arthritis (RA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Reasons to buy the ‘Rheumatoid Arthritis (RA)’ marketed and pipeline drugs assessment report: Get a comprehensive overview of the rheumatoid arthritis market including disease epidemiology, treatment guidelines, clinical trials, deals, and an assessment of marketed and pipeline drugs. Get an insight into MoA, RoA, and molecule types for the leading marketed and pipeline drugs in RA. Assess the pricing and reimbursement of rheumatoid arthritis marketed and pipeline drugs. Get a detailed assessment of the clinical trials taking place within the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.